Cyclophosphamide versus placebo in scleroderma lung disease. - Wikidata - awgldk - TriplyDB

Cyclophosphamide versus placebo in scleroderma lung disease.

Cyclophosphamide versus placebo in scleroderma lung disease.

http://www.wikidata.org/entity/Q34540647

about

Cyclophosphamide for connective tissue disease-associated interstitial lung disease My approach to the treatment of scleroderma Pharmacotherapy of systemic sclerosis Immunotherapy of systemic sclerosis Systemic Sclerosis and Malignancy: A Review of Current Data Current perspectives on the immunopathogenesis of systemic sclerosis Therapeutic Approach to Adult Fibrotic Lung Diseases Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Idiopathic interstitial pneumonias with connective tissue diseases features: A review Management of Systemic-Sclerosis-Associated Interstitial Lung Disease Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials Targeted Therapy in Systemic Sclerosis Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement The role of biologics in treatment of connective tissue disease-associated interstitial lung disease Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis Automated 3D ιnterstitial lung disease εxtent quantification: performance evaluation and correlation to PFTs Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort A joint model for longitudinal measurements and survival data in the presence of multiple failure types.An approach to joint analysis of longitudinal measurements and competing risks failure time data.Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.Robust joint modeling of longitudinal measurements and competing risks failure time data A Bayesian approach to joint analysis of longitudinal measurements and competing risks failure time data.Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects.Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive.Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress.Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.Imaging lung disease in systemic sclerosis.Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.Innovative approaches to the therapy of fibrosis Interpretation of autoantibody positivity in interstitial lung disease and lung-dominant connective tissue disease Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Effect of menopause on the modified Rodnan skin score in systemic sclerosis.Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.Characterisation of patients with interstitial pneumonia with autoimmune features.

P2860

Q24201486-40B55484-2C14-4784-87FA-8791700E4AD3 Q24618843-601C6398-BC2A-4617-952D-927AC275318F Q24629481-D01975B8-1FEE-49DF-8C9F-80BFDD32BF50 Q24634395-8F04B8C3-7A9C-4B97-BEC8-9BEE13B60829 Q26740318-0E898812-B2CA-459B-8D96-46194A597B92 Q26741264-54C7861A-EC19-4004-945C-328B09921384 Q26741569-62171BC2-FF38-4C2B-AB4C-6FDF5EAEE245 Q26773161-1CB59084-BF5B-4DE2-9753-7644DFB6AE7C Q26775753-B51C6973-1546-4951-B24D-C1AC266BA347 Q26799465-2641BA8B-AA6B-4EA0-B478-17E25262DD6D Q26799573-A613FE0C-D489-44C2-ABBA-3C224873DA41 Q27022117-EDBB9BA7-66CB-496B-9D50-F3FEAFCCEB3C Q27024062-44E56C1F-5E1A-497A-9568-335F98819167 Q28072943-D2CA3E2F-697F-45B8-93AD-51D4D966242A Q28080076-39F79FDE-6F28-42C3-A29C-F691EB386D59 Q28082021-01373CEC-24E0-4D12-8063-3951BE5AA4CD Q28388130-3135DFF0-449F-448E-A689-7566CB3AD41F Q28659966-1F66516A-AB0B-4DEE-A04C-9F81DC84D57C Q28743863-8D5A2129-89FE-4CBE-A22A-337024C0B105 Q30490523-32ED470C-9D63-40C6-85F7-B09C3CC92887 Q31080090-82F5124F-91C7-4300-B655-A710740DCAED Q33380516-57DD4B17-E248-4457-B60B-E0E8151C46A8 Q33406378-C895AC03-5245-4411-BA2E-68035FBF63C8 Q33420956-49E23BAE-1312-4E81-AC48-C9DE70FBE34E Q33434238-72318235-C601-4CE1-9ACC-BC0F495CCDE7 Q33588875-E6096882-3739-4099-B09D-C2F0A993AA46 Q33604991-1A5DDDC5-B49A-4E26-B1C4-EA1A23752781 Q33692595-562A8B3E-24E2-4204-A6C6-1137057FFF1F Q33714877-09E8117F-4A52-4D39-B69A-45271C0F8B96 Q33724819-EA0D5DE6-31BA-4DEA-A8AE-4EA55F34198C Q33727800-CFEDF7E9-1179-482E-A87A-444A3688D61F Q33754571-B152C4C0-F850-4E6D-BEBB-254647B4B3BC Q33802001-794B7F0B-4D70-4746-8BDE-2A068C8227FE Q33824140-55513BB3-5843-4FD4-9D98-E9F742A0D015 Q33824245-6B1DF658-F944-487D-880C-1C2C8C5A27D4 Q33891119-04F48D1D-05D3-40C5-BEAC-D8660A9B9D1C Q33892434-E6174B96-6D77-4FDC-91AA-7239EBBD8729 Q33905175-42FC63E0-32C7-41EC-9A64-2D20B5D42900 Q33907242-054DE529-8CD2-4F47-8A9E-0B7CB340F7B1 Q33915673-94EAFBE6-AA63-4712-87D1-28F76BE08E57

P2860

Cyclophosphamide versus placebo in scleroderma lung disease.

http://www.wikidata.org/entity/Q34540647

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cyclophosphamide versus placebo in scleroderma lung disease.

@ast

Cyclophosphamide versus placebo in scleroderma lung disease.

@en

Cyclophosphamide versus placebo in scleroderma lung disease.

@nl

type

label

Cyclophosphamide versus placebo in scleroderma lung disease.

@ast

Cyclophosphamide versus placebo in scleroderma lung disease.

@en

Cyclophosphamide versus placebo in scleroderma lung disease.

@nl

prefLabel

Cyclophosphamide versus placebo in scleroderma lung disease.

@ast

Cyclophosphamide versus placebo in scleroderma lung disease.

@en

Cyclophosphamide versus placebo in scleroderma lung disease.

@nl

P1433

Q34540647-711A581F-A5BA-463D-9A7E-E1AE839ACA35

P1476

Q34540647-678CCBDA-1C60-4B7B-B067-F6586BE6A0B6

P2093

Q34540647-1B0F27BF-C5A2-4069-8C44-8B689CA49F61

Q34540647-1C755A0A-23F2-42C3-B480-76E918F25D15

Q34540647-2925FCEA-D334-43B1-8AFC-D0FDF8B21A44

Q34540647-2ABC09BF-19B9-464F-AB57-5505858590B5

Q34540647-31E63B2D-5333-4689-8E0D-32977C4EBB6E

Q34540647-3ED4E582-8F68-49EA-AB56-A5251469CC9F

Q34540647-7E3AFD65-2408-45E9-8A62-04FE97C57E88

Q34540647-831D4D50-9E61-4223-A5A8-1E72E08B4D80

Q34540647-85376067-B188-41DE-8131-7D59AF86B2E5

Q34540647-88B5E9D2-09CD-4362-861B-90FAA647B2D9

P304

Q34540647-1FA9A527-1BD6-49A2-9EE6-DBF334D0200F

P31

Q34540647-9C7144CE-D669-43B2-B98A-B7970F4BF201

P356

Q34540647-5F9D9D08-AE15-46D5-93F9-0ACD6CE8DA9A

P407

Q34540647-A6BF7CE0-1D5A-4DAF-9B01-F7A1C57F0CAC

P433

Q34540647-04BB3A43-BB3A-45C7-B2CB-725708D0B7C2

P478

Q34540647-101841DA-0C5D-46D6-92FB-C728D3082EAC

P50

Q34540647-3C505CDC-FDCB-422F-B746-B009D6AF344F

Q34540647-65912BAD-4106-4456-8F73-15705FDD44F7

Q34540647-74ED2856-DF1E-438D-BA80-0FC14EE7C06F

Q34540647-7FC85EA7-A717-4722-A090-48D6F35EB4A9

Q34540647-9AB3E8CE-8FD6-40F1-B1ED-35B17205A743

P577

Q34540647-519C4DB8-18E3-47D2-B658-AD592BE83F40

P5875

Q34540647-BE742446-7B9E-4A85-BF19-553058A2C1AE

P698

Q34540647-57CFBAF0-C892-4EEB-BC04-39C6AB21DB42

P921

Q34540647-B5EDA166-0476-4A77-977D-5C24A7F59095

P356

P1433

The New England Journal of Medicine

P1476

Cyclophosphamide versus placebo in scleroderma lung disease

@en

P2093

Arthur Theodore

http://www.w3.org/2001/XMLSchema#string

Barbara White

http://www.w3.org/2001/XMLSchema#string

Barri Fessler

http://www.w3.org/2001/XMLSchema#string

Charles Read

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

David J Riley

http://www.w3.org/2001/XMLSchema#string

Donald P Tashkin

http://www.w3.org/2001/XMLSchema#string

Ed Parsley

http://www.w3.org/2001/XMLSchema#string

Edgar Arriola

http://www.w3.org/2001/XMLSchema#string

Fredrick Wigley

http://www.w3.org/2001/XMLSchema#string

P304

2655-2666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA055120

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Goldin

Charlie Strange

Dean E Schraufnagel

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6993142

http://www.w3.org/2001/XMLSchema#string

P698

16790698

http://www.w3.org/2001/XMLSchema#string

P921